Conditions present in patients who died during the study period (on or before day 110) and late after BMT (after day 110)
| Condition present at death . | On or before day 1103-150 . | After day 1103-151 . | ||||
|---|---|---|---|---|---|---|
| Fluconazole (%) . | Placebo (%) . | P . | Fluconazole (%) . | Placebo (%) . | P . | |
| Fungal infection | ||||||
| Mold | 10 (7) | 6 (4) | .33 | 10 (8) | 6 (6) | .60 |
| Candida spp. | 1 (< 1) | 13 (9) | .001 | 1 (< 1) | 8 (8) | .007 |
| Other infection | ||||||
| Bacteremia | 5 (3) | 2 (1) | .45 | 6 (5) | 10 (11) | .11 |
| CMV pneumonia | 2 (1) | 0 (0) | .50 | 3 (2) | 1 (1) | .44 |
| Bacterial pneumonia | 1 (< 1) | 2 (1) | .62 | 1 (< 1) | 0 (0) | .38 |
| Toxoplasmosis | 0 (0) | 2 (1) | .24 | 0 (0) | 0 (0) | — |
| Respiratory virus | 0 (0) | 1 (< 1) | .49 | 1 (< 1) | 0 (0) | .37 |
| Pneumocystis carinii | 0 (0) | 0 | — | 0 (0) | 1 (1) | .26 |
| Relapse3-152 | 4 (3) | 7 (5) | .33 | 20 (16) | 18 (19) | .57 |
| Idiopathic pneumonia | 3 (2) | 7 (5) | .18 | 6 (5) | 3 (3) | .54 |
| GVHD (no infection) | 2 (1) | 8 (5) | .049 | 1 (< 1) | 3 (3) | .15 |
| Multiorgan failure3-153 | 3 (2) | 4 (3) | .72 | 1 (< 1) | 4 (3) | .20 |
| Unrelated3-155 | 0 (0) | 0 (0) | — | 3 (2) | 3 (3) | .67 |
| Condition present at death . | On or before day 1103-150 . | After day 1103-151 . | ||||
|---|---|---|---|---|---|---|
| Fluconazole (%) . | Placebo (%) . | P . | Fluconazole (%) . | Placebo (%) . | P . | |
| Fungal infection | ||||||
| Mold | 10 (7) | 6 (4) | .33 | 10 (8) | 6 (6) | .60 |
| Candida spp. | 1 (< 1) | 13 (9) | .001 | 1 (< 1) | 8 (8) | .007 |
| Other infection | ||||||
| Bacteremia | 5 (3) | 2 (1) | .45 | 6 (5) | 10 (11) | .11 |
| CMV pneumonia | 2 (1) | 0 (0) | .50 | 3 (2) | 1 (1) | .44 |
| Bacterial pneumonia | 1 (< 1) | 2 (1) | .62 | 1 (< 1) | 0 (0) | .38 |
| Toxoplasmosis | 0 (0) | 2 (1) | .24 | 0 (0) | 0 (0) | — |
| Respiratory virus | 0 (0) | 1 (< 1) | .49 | 1 (< 1) | 0 (0) | .37 |
| Pneumocystis carinii | 0 (0) | 0 | — | 0 (0) | 1 (1) | .26 |
| Relapse3-152 | 4 (3) | 7 (5) | .33 | 20 (16) | 18 (19) | .57 |
| Idiopathic pneumonia | 3 (2) | 7 (5) | .18 | 6 (5) | 3 (3) | .54 |
| GVHD (no infection) | 2 (1) | 8 (5) | .049 | 1 (< 1) | 3 (3) | .15 |
| Multiorgan failure3-153 | 3 (2) | 4 (3) | .72 | 1 (< 1) | 4 (3) | .20 |
| Unrelated3-155 | 0 (0) | 0 (0) | — | 3 (2) | 3 (3) | .67 |
BMT indicates bone marrow transplantation; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
All conditions present at death, except for specific infections, were extracted from previous publication.18 Specific infections present at death were determined with an additional data review. Percentage deaths are calculated relative to total cohort (see text for details).
Percentage deaths are calculated relative to number of patients alive at day 110 (96 placebo, 122 fluconazole). Multiple causes of death are listed for 4 patients (see text).
Included in this group are patients who died with all relapse-related complications.
Included in this group are patients who died with veno-occlusive disease before day 110 (n = 4).
Causes of death thought unrelated to BMT or unrelated disease during the follow-up period included traumatic cerebral hemorrhage (n = 2), gastrointestinal ulcer with bleed (n = 1), pulmonary embolism (n = 1), and ethanol-induced hepatic failure (n = 1).